关注
Martin Voss
Martin Voss
在 mskcc.org 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
31612019
OncoKB: a precision oncology knowledge base
D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ...
JCO precision oncology 1, 1-16, 2017
20252017
Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy
J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ...
Journal of Clinical Oncology 35 (7), 709, 2017
10772017
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
D Miao, CA Margolis, W Gao, MH Voss, W Li, DJ Martini, C Norton, ...
Science 359 (6377), 801-806, 2018
10202018
Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer
MD Hellmann, T Nathanson, H Rizvi, BC Creelan, F Sanchez-Vega, ...
Cancer cell 33 (5), 843-852. e4, 2018
9422018
Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures
Y Şenbabaoğlu, RS Gejman, AG Winer, M Liu, EM Van Allen, ...
Genome biology 17, 1-25, 2016
7922016
Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study
HJ Hammers, ER Plimack, JR Infante, BI Rini, DF McDermott, LD Lewis, ...
Journal of Clinical Oncology 35 (34), 3851, 2017
4682017
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network
AA Hakimi, I Ostrovnaya, B Reva, N Schultz, YB Chen, M Gonen, H Liu, ...
Clinical Cancer Research 19 (12), 3259-3267, 2013
3812013
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ...
Cell 185 (3), 563-575. e11, 2022
3072022
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
A Amin, ER Plimack, JR Infante, MS Ernstoff, BI Rini, DF McDermott, ...
Journal of Clinical Oncology 32 (15_suppl), 5010-5010, 2014
2912014
An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma
AA Hakimi, H Furberg, EC Zabor, A Jacobsen, N Schultz, G Ciriello, ...
Journal of the National Cancer Institute 105 (24), 1862-1870, 2013
2852013
Tumor microenvironment dynamics in clear-cell renal cell carcinoma
L Vuong, RR Kotecha, MH Voss, AA Hakimi
Cancer discovery 9 (10), 1349-1357, 2019
2832019
Hereditary leiomyomatosis and renal cell carcinoma syndrome–associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant …
YB Chen, AR Brannon, A Toubaji, ME Dudas, HH Won, HA Al-Ahmadie, ...
The American journal of surgical pathology 38 (5), 627-637, 2014
2632014
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma
AA Hakimi, YB Chen, J Wren, M Gonen, O Abdel-Wahab, A Heguy, H Liu, ...
European urology 63 (5), 848-854, 2013
2612013
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
BI Rini, D Battle, RA Figlin, DJ George, H Hammers, T Hutson, E Jonasch, ...
Journal for immunotherapy of cancer 7, 1-20, 2019
2272019
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy
MH Voss, AA Hakimi, CG Pham, AR Brannon, YB Chen, LF Cunha, ...
Clinical cancer research 20 (7), 1955-1964, 2014
2252014
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy
C Krishna, RG DiNatale, F Kuo, RM Srivastava, L Vuong, D Chowell, ...
Cancer cell 39 (5), 662-677. e6, 2021
2192021
Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC)
H Hammers, ER Plimack, JR Infante, M Ernstoff, BI Rini, DF McDermott, ...
Annals of Oncology 25, iv361, 2014
2092014
Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma
JJ Hsieh, D Chen, PI Wang, M Marker, A Redzematovic, YB Chen, ...
European urology 71 (3), 405-414, 2017
2082017
Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: data from a randomized phase III trial
AA Hakimi, MH Voss, F Kuo, A Sanchez, M Liu, BG Nixon, L Vuong, ...
Cancer discovery 9 (4), 510-525, 2019
1982019
系统目前无法执行此操作,请稍后再试。
文章 1–20